Sunitinib-induced reversible posterior leukoencephalopathy syndrome after rifampin discontinuation / 대한내과학회지
Korean Journal of Medicine
;
: S188-S191, 2009.
Artículo
en Coreano
| WPRIM
| ID: wpr-139799
ABSTRACT
Sunitinib is an oral tyrosine kinase inhibitor with anti-angiogenic activity that is used for the treatment of advanced renal cell carcinoma and advanced gastrointestinal stromal tumors after failure on imatinib. The most common adverse effects of sunitinib are fatigue, diarrhea, nausea, stomatitis, hypertension, hand-foot syndrome, and cytopenia. Sunitinib was recently reported to be associatedwith reversible posterior leukoencephalopathy syndrome (RPLS). Here, we report the case of a 76-year-old woman with sunitinib- induced RPLS that developed after rifampin discontinuation.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Piperazinas
/
Pirimidinas
/
Pirroles
/
Rifampin
/
Estomatitis
/
Benzamidas
/
Proteínas Tirosina Quinasas
/
Carcinoma de Células Renales
/
Tumores del Estroma Gastrointestinal
/
Diarrea
Límite:
Anciano
/
Femenino
/
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Año:
2009
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS